A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.

http://purl.obolibrary.org/obo/NCIT_C1910

A substance that keeps the testicles and ovaries from making sex hormones by blocking other hormones that are needed to make them. In men, gonadotropin-releasing hormone agonists cause the testicles to stop making testosterone. In women, they cause the ovaries to stop making estrogen and progesterone. Some gonadotropin-releasing hormone agonists are used to treat prostate cancer. Also called GnRH agonist, LH-RH agonist, and luteinizing hormone-releasing hormone agonist.

C1910

CTRP

A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.

Gonadotropin-releasing Hormone Analog

http://purl.obolibrary.org/obo/NCIT_C177537

http://purl.obolibrary.org/obo/NCIT_C176424

http://purl.obolibrary.org/obo/NCIT_C116977

http://purl.obolibrary.org/obo/NCIT_C116978

http://purl.obolibrary.org/obo/NCIT_C128784

http://purl.obolibrary.org/obo/NCIT_C157711

http://purl.obolibrary.org/obo/NCIT_C157712

http://purl.obolibrary.org/obo/NCIT_C1909

Gonadotropin-releasing Hormone Analog

Luteinizing_Hormone-releasing_Hormone_Agonist

Gonadotropin-releasing Hormone Analog

42628

42628

42628

Gonadotropin-releasing Hormone Analog

NCIT:C1910

Gonadotropin-releasing Hormone Analog

Pharmacologic Substance

C1268900

http://purl.obolibrary.org/obo/NCIT_C548